Navigation Links
Spherix Awarded Grant from U.S. Government Under the Patient Protection and Affordable Care Act
Date:11/3/2010

BETHESDA, Md., Nov. 3, 2010 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis; and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its subsidiary, Biospherics Incorporated, has been awarded $469,479 under HR: 3590 – Patient Protection and Affordable Care Act (the "Act") in immediately available funds.

Claire Kruger, Chief Executive Officer of Spherix, said, "This award will allow us to accelerate the initiation of our triglycerides development program to late 2010 to include in vitro and animal studies leading to appropriate human trials. The incidence of metabolic diseases has reached crisis proportions both in the United States and globally, with estimates of 24 million people with Type 2 diabetes and more than 100 million people with elevated triglycerides in the U.S., approximately 10 million of whom are poorly served by current drug regimens. We are very pleased to receive this non-dilutive capital to further advance our clinical development activities, particularly in triglycerides."

Under the Act, $1 billion was made available to stimulate promising therapeutic research for serious and life-threatening diseases by small biotechnology companies. Applicants were required to submit detailed information demonstrating that their research conformed to the parameters of the Act, along with a summary of qualifying expenditures that formed the basis for the award. Spherix submitted two applications for D-tagatose, including one for its use as a drug candidate in the treatment of diabetes and one for its use as a drug candidate in treating high triglycerides.

Individual companies, regardless of the number of applications filed, were eligible to receive awar
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Spherix Reports Second Quarter Earnings
2. Growth Achieved in Spherixs Health Sciences Consulting Business
3. Spherix D-tagatose to be Supplied by Inalco SpA
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Spherix Postpones 2009 Annual Shareholders Meeting to Share Interim Diabetes Clinical Trial Data
6. Spherix Elects New Independent Director, and Elects Chairman of the Board
7. Spherix Reports First Quarter 2009 Earnings
8. Spherix Announces Positive Phase 2 Study Results
9. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
10. Spherix to Present at Annual OneMedPlace Finance Forum and at EBD Biotech Showcase in San Francisco
11. Spherix Reports Third Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... is pleased to announce the appointment of Dr. ... Biochemistry. Scott joins the company after previous scientific leadership positions ... course of his nearly 20 year career in therapeutics ... recognized thought leader in the biosensor field and particularly ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ... focus on Omega-3 therapies for cardiovascular disease and overall health ... Company,s accomplishments in 2014 and its outlook for 2015 from ... Fellow Shareholders, We would like to take this ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... OrbusNeich announced that data from multiple clinical trials supporting ... cases where prolonged dual antiplatelet therapy (DAPT) is not ... "How to assess and treat patients who are not ... 2011 in Paris. Presenters discussed current treatment ...
... LAKE CITY, May 19, 2011 Paradigm Medical Industries, ... notification from its Italian partner, Costruzione Strumenti Oftalmici (CSO), ... pages and 24 attachments to the U.S. Food and ... for the Paramax™. This supportive information was submitted to ...
Cached Medicine Technology:OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 2OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 3OrbusNeich's Genous™ Stent is Safe and Effective in Cases Where Prolonged Dual Antiplatelet Therapy is Not Advisable as Presented at EuroPCR 2011 4Paramax™ Moves Closer To FDA Approval 2
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of Cruz Chiropractic ... treated just about every type of injury that can result from ... same twenty-plus years, the team at Doctors on Liens ... possible doctor. With the combined breadth of experience between ...
(Date:1/22/2015)... 2015 A study recently published ... journal Medicine & Science in Sports & Exercise ... help reduce gastrointestinal (GI) problems associated with physical ... in the double-blind, placebo-controlled study took 10 grams ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Mass. (PRWEB) January 22, 2015 EBSCO ... (AMA) are expanding their relationship in an effort to ... around the world. While EBSCO has long made AMA journals ... a sales agent for The JAMA Network. , ...
Breaking Medicine News(10 mins):Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Records Into a User,s New ... Google Health Profile, ... delivers a variety of integrated healthcare services,announced today that it is ... that launched yesterday which allows users to,store, organize, and manage their ...
... Healthcare Provider vertical will be first to obtain certification ... for GE Centricity Enterprise software, ... SAY ), a leading global consulting and information,technology services ... customers deploying healthcare IT,solutions based on GE Centricity Enterprise software., ...
... to have operation before emergency procedure is needed , , TUESDAY, ... than white men to have elective surgery to repair abdominal ... data on men 65 and older who had elective or ... conclusion. , An abdominal aortic aneurysm occurs when there,s a ...
... PRINCETON JUNCTION, N.J., May 20 Lutronic, one ... laser systems,announced today that it has received FDA ... wavelength system. This dual pulse Q-Switched Nd:,Yag laser ... II. It is,specifically designed to treat a wide ...
... designing a preventive HIV vaccine, the National Institute of ... Institutes of Health, is launching a new program to ... can produce antibodies with the capacity to neutralize HIV. ... the scientific foundation of HIV vaccine research through a ...
... Recognition Highlights Organization,s Commitment to Environmental Health, ... Permanente received the,"System for Change" award for ... Excellence Summit in Pittsburgh., The award, ... to gather,environmental data, set goals, and encourage ...
Cached Medicine News:Health News:UNIVAL, Inc. Becomes a Google Health(TM) Integrated Service 2Health News:GE and Satyam Announce Global Alliance to Provide Healthcare IT Services 2Health News:GE and Satyam Announce Global Alliance to Provide Healthcare IT Services 3Health News:GE and Satyam Announce Global Alliance to Provide Healthcare IT Services 4Health News:Black Men Less Likely to Choose Elective Stomach Aorta Surgery 2Health News:Lutronic Inc. Announces FDA Clearance of Its Spectra VRM III Q-Switched Nd: Yag Laser System for Treating a Broad Spectrum of Dermatological and Aesthetic Conditions 2Health News:Lutronic Inc. Announces FDA Clearance of Its Spectra VRM III Q-Switched Nd: Yag Laser System for Treating a Broad Spectrum of Dermatological and Aesthetic Conditions 3Health News:NIAID to advance B-cell approach to HIV vaccines 2Health News:NIAID to advance B-cell approach to HIV vaccines 3Health News:Kaiser Permanente Wins National Green Awards 2Health News:Kaiser Permanente Wins National Green Awards 3
CleanBox DNA workstation with two 254nm UV lambs & 12-hr timer, 90cm (36-inch)width, single door, 115V (w/crating)...
... highthroughput reading of tube racks. Its camera-based vision ... one second per rack, making it ideal for ... the reader allows a rack to be read ... arms. An optical safety switch prevents a rack ...
... Polypropylene workbench top with powder-coated ... from 25"-34". Available in hundreds ... include shelves, drawers, light fixtures ... an expert in custom building ...
Perforated or Rod Top, Free Standing or Wall Mounted, Storage Cubby Optional, Polypropylene Construction...
Medicine Products: